Abstract
Medications to treat pain are in widespread use and any change in the risk of fracture may consequently have a significant impact at a population level. Strong analgesics of the opiate and opiate-like group are associated with an increased risk of fractures probably from an increased risk of falls resulting from the dizziness induced by these drugs. However, not all strong analgesics are associated with an increased risk of fractures. The differences are not readily explained from variations in pharmacokinetic properties. Weak analgesics mainly interact with the prostaglandin system; these drugs include non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid and acetaminophen. Acetaminophen is associated with an increased risk of fractures while acetylsalicylic acid is not. Some but not all NSAIDs are associated with an increased fracture risk, and the differences are not explained by variations in pharmacokinetic properties. More research is needed to determine if some analgesics are safer than others with respect to fracture risk.
Keywords: Pain-Relief Medication, Fractures, analgesics, opiate, prostaglandin system, non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid, acetaminophen
Current Drug Safety
Title: Pain-Relief Medication and Risk of Fractures
Volume: 3 Issue: 3
Author(s): Peter Vestergaard
Affiliation:
Keywords: Pain-Relief Medication, Fractures, analgesics, opiate, prostaglandin system, non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid, acetaminophen
Abstract: Medications to treat pain are in widespread use and any change in the risk of fracture may consequently have a significant impact at a population level. Strong analgesics of the opiate and opiate-like group are associated with an increased risk of fractures probably from an increased risk of falls resulting from the dizziness induced by these drugs. However, not all strong analgesics are associated with an increased risk of fractures. The differences are not readily explained from variations in pharmacokinetic properties. Weak analgesics mainly interact with the prostaglandin system; these drugs include non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid and acetaminophen. Acetaminophen is associated with an increased risk of fractures while acetylsalicylic acid is not. Some but not all NSAIDs are associated with an increased fracture risk, and the differences are not explained by variations in pharmacokinetic properties. More research is needed to determine if some analgesics are safer than others with respect to fracture risk.
Export Options
About this article
Cite this article as:
Vestergaard Peter, Pain-Relief Medication and Risk of Fractures, Current Drug Safety 2008; 3 (3) . https://dx.doi.org/10.2174/157488608785699504
DOI https://dx.doi.org/10.2174/157488608785699504 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
High-Density Lipoprotein-Raising Strategies: Update 2010
Current Pharmaceutical Design Antioxidant to Treat Osteoarthritis: Dream or Reality?
Current Drug Targets Pharmacological Aspects and Potential Use of Phloretin: A Systemic Review
Mini-Reviews in Medicinal Chemistry Developments in Imaging Technologies Related to Hypertensive Cardiovascular Diseases
Current Pharmaceutical Design Relationships of Birthweight and Postnatal Growth with Metabolic Risk Factors in Junior School Children in Korea
Current Hypertension Reviews Critical Congenital Heart Disease in Neonates: A Review Article
Current Pediatric Reviews Diabetic Cardiomyopathy and Oxidative Stress: Role of Antioxidants
Cardiovascular & Hematological Agents in Medicinal Chemistry New Therapeutic Approaches to Arterial Calcification Via Inhibition of Transglutaminase andβ-Catenin Signalin
Current Pharmaceutical Design The Possible Therapeutic Actions of Peroxisome Proliferator-Activated Receptor α(PPARα) Agonists,PPARγ Agonists,3-Hydroxy-3- Methylglutaryl Coenzyme A (HMG-CoA)Reductase Inhibitors,Angiotensin Converting Enzyme (ACE)Inhibitors and Calcium (Ca)-Antagonists on Vascular Endothelial Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Improving Patient Compliance with Hypertension Treatment: Mission Possible?
Current Vascular Pharmacology Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics Ethical Considerations in Conducting Pediatric and Neonatal Research in Clinical Pharmacology
Current Pharmaceutical Design Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Genetic Polymorphism of LDLR (rs688) is Associated with Primary Intracerebral Hemorrhage
Current Neurovascular Research Taurine, Bone Growth and Bone Development
Current Nutrition & Food Science The Neuroprotective Effect of Ginkgo biloba Leaf Extract and its Possible Mechanism
Central Nervous System Agents in Medicinal Chemistry Inflammation in Cardiovascular Disease and Regulation of the Actin Cytoskeleton in Inflammatory Cells: The Actin Cytoskeleton as a Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Mast Cells and Inflammatory Heart Disease: Potential Drug Targets
Cardiovascular & Hematological Disorders-Drug Targets Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures
Current Pharmaceutical Design